Profile: Exact Sciences Corp (EXAS.W)
19 Dec 2013
Exact Sciences Corporation, incorporated on February 10, 1995, is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company’s Cologuard test is a non-invasive, stool-based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The target sensitivity rate of its Cologuard test for cancer is equal to or greater than 85% at a specificity of 90%.
The Company’s Cologuard test includes methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. In November 2012, it completed enrollment for its pivotal FDA clinical trial with over 10,000 patients enrolled at 90 enrollment sites in the United States and Canada.
The Company competes with Epigenomics AG, Gene News and Quest Diagnostics.
Exact Sciences Corp
441 Charmany Drive
MADISON WI 53719